Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.9252W HIGH $19.14
Volume
28.94 K
Value Traded
385.62 K
Short % Float
5.83%
-2.64%Week
-6.86%1 Month
-5.43%3 Month
+98.49%6 Month
-97.29%5 Year
-96.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
92.65 M
EPS (TTM)
-1.66
P/E Ratio
-
Ent. Value
82.78 M
Total Shares
10.04 M
Float Shares
6.93 M
Insiders
30.97%
Institutions
48.12%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ATRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Atara Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Atara Biotherapeutics, Inc.
569Total events
5Upcoming
127Tier-1 (high impact)
2014 to 2028Coverage
Upcoming catalysts 2
Event history 50
●BLA SubmissiontabelecleucelFiledRegulatory Filing
Tabelecleucel BLA resubmitted to FDA by partner Pierre Fabre Pharmaceuticals
relapsed/refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) following solid organ transplant (SOT) or hematopoietic cell transplant (HCT)source ↗
▲FDA Feedback ReceivedtabelecleucelFiledFDA Meeting
Productive FDA meeting; path forward for BLA resubmission discussed
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
●Quarterly UpdateCorporate
Atara Biotherapeutics reports second quarter 2026 financial results
◆CRL ResubmissiontabelecleucelFiledFDA Decision
Intended resubmission of tab-cel BLA with updated dataset from ALLELE study
R/R EBV+ PTLD following solid organ transplant or hematopoietic cell transplantsource ↗
◆Timing GuidancetabelecleucelFiledPresentation
Atara anticipates providing a further regulatory update later this quarter
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
◆Timing GuidancePresentation
Deadline to request lead plaintiff appointment in class action lawsuit
▲FDA Feedback ReceivedtabelecleucelFiledFDA Meeting
Productive FDA meeting; path forward for BLA resubmission discussed
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
◆Type A MeetingtabelecleucelFiledFDA Meeting
Type A meeting with FDA to discuss CRL for tab-cel BLA
R/R EBV+ PTLD following solid organ transplant or hematopoietic cell transplantsource ↗
▼Short Report ActivistCorporate
Securities class action lawsuit filed against Atara Biotherapeutics
●Type A MeetingtabelecleucelFiledFDA Meeting
Type A meeting held with FDA regarding tabelecleucel BLA
relapsed/refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)source ↗
◆Timing GuidancetabelecleucelFiledPresentation
Regulatory update expected in Q2 2026
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
▲FDA Feedback ReceivedtabelecleucelFiledFDA Meeting
FDA guidance provided on resubmission of tabelecleucel BLA
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
◆Type A MeetingtabelecleucelFiledFDA Meeting
Type A meeting scheduled between Pierre Fabre and FDA to discuss CRL
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
◆Type A MeetingtabelecleucelFiledFDA Meeting
Partner Pierre Fabre submitted request for Type A meeting with FDA
EBV+ PTLDsource ↗
▲Milestone PaymentCorporate
Renegotiated milestone payment due date with HCRx extended from June 30, 2026 to January 1, 2028
◆PDUFA DatetabelecleucelFiledRegulatory Filing
PDUFA target action date for tab-cel BLA
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)source ↗
▲Milestone PaymenttabelecleucelFiledCorporate
$40M milestone payment from Pierre Fabre upon FDA approval
EBV+ PTLDsource ↗
▼Complete Response LettertabelecleucelFiledFDA Decision
FDA issued Complete Response Letter for tabelecleucel BLA
EBV+ PTLDsource ↗
▼Complete Response LetterEBVALLOFDA Decision
FDA issued Complete Response Letter for EBVALLO BLA
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)source ↗
▼Complete Response LettertabelecleucelFiledFDA Decision
FDA issued Complete Response Letter for tab-cel BLA
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
●Partnership / LicenseEBVALLOCorporate
Amendment to commercialization agreement with Pierre Fabre Medicament
▲FDA Filing AcceptedtabelecleucelFiledRegulatory Filing
FDA accepted BLA filing for tab-cel with Priority Review
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)source ↗
●BLA SubmissiontabelecleucelFiledRegulatory Filing
BLA resubmission for tab-cel accepted by FDA
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)source ↗
▲FDA Filing AcceptedtabelecleucelFiledRegulatory Filing
FDA accepted BLA filing for tab-cel
Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)source ↗
▲Priority ReviewtabelecleucelFiledRegulatory Filing
Priority Review granted for tab-cel BLA
EBV+ PTLDsource ↗
▲Partnership / LicensetabelecleucelFiledCorporate
Transfer of operational activities to Pierre Fabre completed
EBV+ PTLDsource ↗
●BLA SubmissiontabelecleucelFiledRegulatory Filing
BLA resubmission for tabelecleucel (tab-cel) for EBV+ PTLD
Epstein-Barr virus positive post-transplant lymphoproliferative diseasesource ↗
◆Topline ReadoutATA3219Clinical Data
Initial clinical data for ATA3219 in ERL expected mid-2025
Extrarenal Systemic Lupus Erythematosus (ERL)source ↗
▼Equity OfferingCorporate
Underwritten offering of common stock and pre-funded warrants for $16M gross proceeds
▲Partnership / LicensetabelecleucelFiledCorporate
Transfer of all manufacturing responsibility to Pierre Fabre Laboratories
Post-Transplant Lymphoproliferative Disease (PTLD)source ↗
▼Restructuring LayoffsCorporate
Workforce reduction of approximately 30% due to CAR T program winddown
Past FDA Catalysts and PDUFA Decisions
How ATRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-12 | Tabelecleucel (tab-cel®) | PDUFA Date CRL | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D21 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 92%
Micro Cap(rank 605 of 658)
Percentile Rank
Atara Biotherapeutics, Inc. faces pipeline headwinds (21/100), with $67M risk-adjusted pipeline value, led by EBV-specific T cells in EBV-induced Lymphomas (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EBV-specific T cells Monoclonal antibodyCompletedNCT01498484 | EBV-induced Lymphomas | Phase 2 | COMPLETED | 87 | Jul 1, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every ATRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ATA188 | non-active progressive multiple sclerosis | Phase 2 | 2023-11-08 | disability improvement treatment arm: 6 percent; disability improvement placebo: 33 percent; placebo rate: 16 percent; expected placebo rate: 4-6 percentRead More | Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 for Non-Active Progressive Multiple Sclerosis Primary Endpoint of Confirmed Disability Improvement at 12 Months Not AchieRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cherry Brian NDirector | Buy | 104,166 166,486 held | $9.60 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ATRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 0.9 % | 17.82 M | 1.55 M | 1,458.34% ( 1.45 M) |
ATRA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATRA ranks across every disease it competes in
Competitive Position is a premium feature
See how ATRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATRA News
ATRA▲ +5.6%on this news· ran to +17% by day 3
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
Atara Biotherapeutics has announced that its partner, Pierre Fabre Pharmaceuticals, has resubmitted the Biologics License Application for tabelecleucel to the FDA. This resubmission marks a critical step in the regulatory process for the therapy, which is designed to treat patients with cancer and autoimmune diseases. The collaboration highlights Atara's commitment to advancing innovative T-cell immunotherapy.
Read more →ATRA▼ -7.8%on this news
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
Atara Biotherapeutics announced its financial results for the second quarter of 2026, highlighting significant operational progress. The company emphasized the advancements in its T-cell immunotherapy platform and noted a successful Type A meeting with Pierre Fabre Pharmaceuticals. This quarter marks a pivotal moment for Atara as it continues to develop therapies for cancer and autoimmune diseases.
Read more →ATRAAtara Biotherapeutics Announces Changes to Its Board of Directors
Atara Biotherapeutics has announced changes to its Board of Directors. The details regarding the specific changes or the implications of these adjustments were not disclosed in the article. This announcement reflects the company's ongoing efforts to align its leadership with its strategic goals.
Read more →ATRA▲ +11.7%on this newsshared move
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
Atara Biotherapeutics has announced its financial results and operational progress for the first quarter of 2026. The report highlights the company's ongoing efforts and developments in its therapeutic pipeline. However, specific details regarding financial performance and operational milestones were not disclosed in the article.
Read more →ATRA▲ +92.8%on this newsshared move
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Eps
Atara Biotherapeutics has provided an update on the regulatory progress of tabelecleucel following a Type A meeting with the FDA. The meeting discussed a potential pathway for resubmitting the Biologics License Application (BLA) for tabelecleucel, where the FDA indicated that a single arm study with appropriate historical controls could be adequate. Pierre Fabre Pharmaceuticals plans to submit additional patient data from the Phase 3 ALLELE study as part of the resubmission. Atara expressed gratitude for the collaborative engagement with the FDA and anticipates further updates in the third quarter.
Read more →ATRA▼ -9.7%on this news· ran to -21% by day 3
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
Atara Biotherapeutics has announced its financial results for Q4 and full year 2025, showing a reduced net loss compared to 2024. The company is focusing on cost-reduction strategies while supporting its partner, Pierre Fabre Pharmaceuticals, in addressing FDA concerns regarding tabelecleucel for post-transplant lymphoproliferative disease. A Type A meeting with the FDA is scheduled to discuss these issues.
Read more →ATRA▲ +10.8%on this newsshared move
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
Atara Biotherapeutics has scheduled a Type A meeting with the FDA to discuss the Complete Response Letter regarding the Biologics License Application for tabelecleucel, in collaboration with Pierre Fabre Pharmaceuticals. The meeting aims to address the points raised in the CRL and facilitate a resubmission with new efficacy data. Atara's CEO expressed optimism about the meeting and anticipates providing a regulatory update in the second quarter.
Read more →ATRAAtara Biotherapeutics Provides a Business Update
Atara Biotherapeutics announced an amendment to its agreement with HealthCare Royalty, extending a $9 million cash payment due date to January 1, 2028. This extension allows Atara to focus on addressing FDA concerns related to tabelecleucel, a therapy for EBV+ PTLD. The company remains optimistic about its potential and the need for treatment options in the U.S.
Read more →ATRA▼ -57%on this news· ran to -68% by day 1
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
Atara Biotherapeutics announced that the FDA issued a Complete Response Letter for its EBVALLO (tabelecleucel) BLA, stating it cannot be approved in its current form. The FDA acknowledged resolved GMP compliance issues but reversed its stance on the ALLELE trial's adequacy for effectiveness evidence. Atara plans to engage with the FDA to find a path forward for accelerated approval.
Read more →ATRA▼ -57%on this news· ran to -68% by day 1
PIERRE FABRE PHARMACEUTICALS STATEMENT REGARDING RECEIPT OF COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION
Pierre Fabre Pharmaceuticals received a Complete Response Letter from the FDA regarding the tabelecleucel Biologics License Application, expressing disappointment and concern over the decision, which may hinder access to treatment for patients with EBV+ PTLD. The company plans to engage with the FDA to seek a path forward.
Read more →ATRAAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLO and Drug Administration has issued a Complete Response Letter (CRL)
Atara Biotherapeutics announced that the FDA has issued a Complete Response Letter for its biologics license application (BLA) for EBVALLO (tabelecleucel). The letter indicated that the FDA can no longer support the adequacy of the ALLELE trial, despite prior confirmations. While Atara has resolved previously identified GMP compliance issues, they now face new challenges regarding trial design. Atara plans to work with Pierre Fabre and the FDA to navigate a path towards accelerated approval for this treatment, which serves patients with limited options.
Read more →ATRAAtara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026
Atara Biotherapeutics reported its third quarter financial results and detailed its progress regarding the Biologics License Application (BLA) for tab-cel, aimed at treating EBV+ PTLD. The BLA has been accepted by the FDA with a target action date set for January 10, 2026. Additionally, Atara has transitioned much of its tab-cel operations to Pierre Fabre, allowing for potential milestone payments. However, the company announced a workforce reduction of approximately 29%, which may affect its strategic execution moving forward.
Read more →ATRA▼ -5.8%on this news
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026
Atara Biotherapeutics reported its second-quarter financial results highlighting operational progress and announced the resubmission of its Biologics License Application (BLA) for tab-cel for EBV+ PTLD. The BLA has been given Priority Review with a target action date of January 10, 2026. The company has transferred its tab-cel activities to Pierre Fabre Laboratories and expects a $40 million milestone payment upon the BLA's approval. Despite a decrease in total revenues year-over-year, Atara anticipates an overall decrease in operating expenses for 2025, enhancing its financial position.
Read more →ATRAAtara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel Atara Biotherapeutics Resubmits Tabelecleucel (Tab-cel ) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease to the U.S. FDA
Atara Biotherapeutics has announced the resubmission of its Biologics License Application (BLA) for tabelecleucel (tab-cel) to the U.S. FDA for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. The resubmission addresses previous manufacturing concerns raised by the FDA and is backed by strong clinical data. Upon approval, Atara is set to receive a $40 million milestone payment from Pierre Fabre Laboratories, highlighting potential financial benefits. However, uncertainties surrounding cash flow and timeline for FDA review present risks for the company.
Read more →ATRA▲ +15.1%on this news
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing
Atara Biotherapeutics reported its first quarter 2025 financial results, highlighting significant operational changes. The company has transferred all manufacturing responsibilities to Pierre Fabre Laboratories and expects to reduce operating expenses by 65% by 2025. Additionally, Atara secured $16 million in financing to extend its cash runway through early 2026 while assessing strategic options for future operations. Despite these positive developments, the company is facing regulatory uncertainties, including a pending Type A meeting with the FDA regarding its BLA submission for tab-cel.
Read more →ATRAAtara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
Atara Biotherapeutics reported its fourth quarter and full year 2024 financial results, revealing a focus on the EBVALLO program amidst significant operational changes. The company is currently engaged with the FDA to resolve issues preventing the submission of a Biologics License Application (BLA) for EBVALLO after receiving a Complete Response Letter. In efforts to streamline operations, Atara has paused CAR-T program developments and cut its workforce by about 50%. Financial results indicate a reduced net loss; however, ongoing challenges with funding and clinical holds remain.
Read more →ATRA▼ -7.9%on this news· ran to +25% by day 3
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLOTM (tabelecleucel) and ATA3219 U.S. FDA issues clinical hold on EBVALLOTM (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL)
Atara Biotherapeutics has announced that the U.S. FDA has placed a clinical hold on its EBVALLO and ATA3219 clinical programs. This hold is due to GMP compliance issues at a third-party manufacturing facility, which have been linked to a recent Complete Response Letter. While treatment for existing patients can continue, new patient enrollment has been paused. Atara is collaborating with the FDA to address the concerns and intends to submit the necessary data to resolve the hold.
Read more →About Atara Biotherapeutics, Inc.
Headquarters1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
Founded2012
BIOPHARMAWATCH ELITE PLUS
Trade the next ATRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime